The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment

Seham Abou Shousha1, Suzan Baheeg2, Hossam Ghoneim1

  • 1Medical Research Institute, Immunology and Allergy Department, Alexandria University, Alexandria, Egypt.

Breast Disease
|June 19, 2023
PubMed

Insights

This study introduces a novel immunotherapy targeting the tumor microenvironment (TME) to combat breast cancer. By blocking FasL and protecting immune cells, the approach significantly enhanced tumor cell apoptosis and reduced cancer stem cells (CSCs).

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Tumor cells evade immune detection via the tumor microenvironment (TME).
  • Fas Ligand (FasL) expressed by tumor cells can induce apoptosis in immune cells, hindering anti-cancer responses.
  • Fas/FasL signaling is implicated in maintaining cancer stem cells (CSCs), promoting tumor aggressiveness and resistance.

Purpose of the Study:

  • To investigate a novel immunotherapeutic strategy targeting FasL-mediated immune evasion in breast cancer.
  • To assess the efficacy of blocking FasL on tumor cells and protecting peripheral blood mononuclear cells (PBMCs) within a TME model.

Main Methods:

  • Utilized a tissue culture system mimicking the TME.
  • Employed recombinant Fas (rFas) molecules to block overexpressed FasL on tumor cells.
  • Supplemented cultures with PBMCs pre-treated with anti-Fas monoclonal antibody (mAb) to protect them from tumor counterattack.

Main Results:

  • Significantly increased tumor cell apoptosis observed in cultures treated with rFas molecules and anti-Fas PBMCs.
  • A notable decrease in CD44 expression, a marker for CSCs, was recorded.
  • Both rFas-enriched and anti-Fas treated PBMC-enriched cultures showed enhanced anti-tumor effects compared to controls.

Conclusions:

  • The proposed immunotherapeutic strategy shows promise for treating breast cancer by overcoming immune evasion.
  • Blocking FasL and protecting immune cells can augment anti-tumor immunity and inhibit cancer stemness.
  • This approach warrants further investigation as a potential treatment for breast cancer.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K